KROS insider ownership: who sold, why, and what they still hold

What stands out

Jean Bienaime bought 7K shares for $76K, first on Mar 9, 2026. These are the first by current officers or directors since Apr 13, 2020.Purchase, Mar 9, 2026

Outside holders and shareholders represented on the board, not part of management, sold heavily: ADAR1 Capital Management, LLC ($95.7M) and Tomer Kariv ($85.0M).ADAR1 Capital Management, LLC: largest sale, Oct 15, 2025 · Tomer Kariv: largest sale, Oct 15, 2025

A share of stake is shown for 0 of the 9 officers and directors who sold. 14 are left out

Left out: Julius Knowles, Jasbir Seehra, Carl Gordon, Keith Regnante, Esther Cho, Lorena Lerner, Annita Tanini, Jean Bienaime, Nima Farzan, Tomer Kariv, Mary Gray, Alpna Seth, Charles Newton and Anne Prener (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Esther Cho

Chief Legal Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$124KTo cover taxes

Jasbir Seehra

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$113KTo cover taxes

Lorena Lerner

Chief Scientific Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$100KTo cover taxes

Keith Regnante

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$77KTo cover taxes

Julius Knowles

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$28KDisclosed plan

All 9 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Aug 18, 20263 executives sold 9.3K shares ($95K) to cover taxes on vesting stock.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Esther Cho Chief Legal Officer	4,485	$10.29	n/a	n/a	Aug 18, 2026	Aug 20, 2026
Lorena Lerner Chief Scientific Officer	3,568	$10.29	n/a	n/a	Aug 18, 2026	Aug 20, 2026
Annita Tanini Corp. Controller & VP, Finance	1,224	$10.29	n/a	n/a	Aug 18, 2026	Aug 20, 2026

Outside holders, reported separately

ADAR1 Capital Management, LLC sold $95.7M and Tomer Kariv (for the outside shareholder represented on the board) sold $85.0M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Keros Therapeutics, Inc. CEO selling stock?

Yes. Jasbir Seehra sold 7K shares ($113K) in the past 12 months, none of it under a trading plan disclosed in the filings.

Why are Keros Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 18% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 82% were to cover taxes. A trading plan schedules sales in advance.

Are any Keros Therapeutics, Inc. insiders buying?

Yes. 1 officer or director reported 6 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold9 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Esther Cho Chief Legal Officer	$124K 9.2K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Jasbir Seehra Chief Executive Officer, Director	$113K 7K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Lorena Lerner Chief Scientific Officer	$100K 7.4K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Keith Regnante Chief Financial Officer	$77K 4.7K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Julius Knowles Director	$28K 2.6K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Nima Farzan Director	$28K 2.6K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Alpna Seth Director	$28K 2.6K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Annita Tanini Corp. Controller & VP, Finance	$13K 1.2K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Charles Newton Director	$11K 1.1K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

Board members representing outside shareholders, reported separately: Tomer Kariv (the shareholder sold $85.0M), Carl Gordon. Details

Outside holder, reported separately: ADAR1 Capital Management, LLC (a 10% owner, not part of management). Sold $95.7M (5.39M shares) from Oct 15, 2025 to Oct 15, 2025. Latest filing

Outside holder, reported separately: ORBIMED ADVISORS LLC (an outside shareholder, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 14 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Julius Knowles

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Julius Knowles are complete.

Director

n/a

−2.6K

n/a

Vesting, gifts, unvested awards and holding lines for Julius Knowles

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Julius Knowles are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$46.31	May 29, 2034	$0
10,500	$14.82	Jun 3, 2035	$0
7,433	$10.50	Jun 2, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Jasbir Seehra

Chief Executive Officer, Director

n/a

−7K

n/a

Vesting, gifts, unvested awards and holding lines for Jasbir Seehra

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jasbir Seehra are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
197,444	$0.30	Mar 25, 2028	$2.0M
125,000	$56.18	Feb 12, 2034	$0
125,000	$63.61	Feb 22, 2034	$0
62,500	$63.61	Feb 22, 2034	$0
217,000	$15.52	Feb 23, 2036	$0
100,000	$15.52	Feb 23, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Carl Gordon

Director

n/a

Vesting, gifts, unvested awards and holding lines for Carl Gordon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Carl Gordon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$46.31	May 29, 2034	$0
10,500	$14.82	Jun 3, 2035	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Keith Regnante

Chief Financial Officer

n/a

−4.7K

n/a

Vesting, gifts, unvested awards and holding lines for Keith Regnante

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Keith Regnante are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
53,622	$16.00	Apr 6, 2030	$0
40,000	$56.18	Feb 12, 2034	$0
60,000	$15.52	Feb 23, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Esther Cho

Chief Legal Officer

n/a

−9.2K

n/a

Vesting, gifts, unvested awards and holding lines for Esther Cho

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Esther Cho are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,968	$29.02	May 3, 2030	$0
20,000	$70.93	Jan 9, 2031	$0
25,000	$46.30	Jan 20, 2032	$0
50,000	$54.38	Feb 15, 2033	$0
50,000	$56.18	Feb 12, 2034	$0
80,000	$15.52	Feb 23, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Lorena Lerner

Chief Scientific Officer

n/a

−7.4K

n/a

Vesting, gifts, unvested awards and holding lines for Lorena Lerner

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lorena Lerner are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,879	$43.99	May 14, 2032	$0
7,500	$54.38	Feb 15, 2033	$0
23,000	$56.18	Feb 12, 2034	$0
75,000	$15.52	Feb 23, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Annita Tanini

Corp. Controller & VP, Finance

n/a

−1.2K

n/a

Vesting, gifts, unvested awards and holding lines for Annita Tanini

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Annita Tanini are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,000	$28.74	May 28, 2030	$0
6,000	$70.93	Jan 9, 2031	$0
7,500	$46.30	Jan 20, 2032	$0
10,000	$54.38	Feb 15, 2033	$0
14,800	$56.18	Feb 12, 2034	$0
7,800	$15.52	Feb 23, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Jean Bienaime

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jean Bienaime

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jean Bienaime are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
17,600	$48.67	Jun 2, 2034	$0
10,500	$14.82	Jun 3, 2035	$0
7,433	$10.50	Jun 2, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Nima Farzan

Director

n/a

−2.6K

n/a

Vesting, gifts, unvested awards and holding lines for Nima Farzan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Nima Farzan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$46.31	May 29, 2034	$0
10,500	$14.82	Jun 3, 2035	$0
7,433	$10.50	Jun 2, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Tomer Kariv

Director

n/a

Vesting, gifts, unvested awards and holding lines for Tomer Kariv

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Tomer Kariv are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$46.31	May 29, 2034	$0
10,000	$46.31	May 29, 2034	$0
10,500	$14.82	Jun 3, 2035	$0
10,500	$14.82	Jun 3, 2035	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Mary Gray

Director

n/a

Vesting, gifts, unvested awards and holding lines for Mary Gray

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mary Gray are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$46.31	May 29, 2034	$0
10,500	$14.82	Jun 3, 2035	$0
7,433	$10.50	Jun 2, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Alpna Seth

Director

n/a

−2.6K

n/a

Vesting, gifts, unvested awards and holding lines for Alpna Seth

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alpna Seth are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,000	$46.31	May 29, 2034	$0
10,500	$14.82	Jun 3, 2035	$0
7,433	$10.50	Jun 2, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Charles Newton

Director

n/a

−1.1K

n/a

Vesting, gifts, unvested awards and holding lines for Charles Newton

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Charles Newton are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,788	$11.35	Mar 8, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Anne Prener

Director

n/a

Vesting, gifts, unvested awards and holding lines for Anne Prener

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Anne Prener are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,870	$10.88	Jun 30, 2036	$0

Estimate: options held × ($10.29 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close.

Holdings and share of stake for Keros Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$523K of sales by plan status, purpose, seller and month

Officer and director open-market sales: $523K across 38,625 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $96K · 18%

82%

The lighter segment is sales with no plan disclosed in the filing ($427K), including tax-related sales outside a plan.

Taxes

$427K of sales (81.7%) cite tax obligations in their footnotes. Example: Annita Tanini, Aug 18, 2026

Purchases · 1 buyer (6 trades)

1 officer or director bought shares in this period, in 6 trades(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 8 purchase trades.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Esther Cho Chief Legal Officer	9.2K	$124K	0%	24%	Feb 18, 2026 to Aug 18, 2026
Jasbir Seehra Chief Executive Officer, Director	7K	$113K	0%	22%	Feb 19, 2026 to Feb 19, 2026
Lorena Lerner Chief Scientific Officer	7.4K	$100K	0%	19%	Feb 18, 2026 to Aug 18, 2026
Keith Regnante Chief Financial Officer	4.7K	$77K	0%	15%	Feb 18, 2026 to Feb 18, 2026
Julius Knowles Director	2.6K	$28K	100%	5%	Jun 4, 2026 to Jun 4, 2026
Nima Farzan Director	2.6K	$28K	100%	5%	Jun 4, 2026 to Jun 4, 2026
Alpna Seth Director	2.6K	$28K	100%	5%	Jun 4, 2026 to Jun 4, 2026
Annita Tanini Corp. Controller & VP, Finance	1.2K	$13K	0%	2%	Aug 18, 2026 to Aug 18, 2026
Charles Newton Director	1.1K	$11K	100%	2%	Jun 11, 2026 to Aug 18, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$0	$0	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$332K	$0	$332K	$0
Mar 2026	$0	$0	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$90K	$90K	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$101K	$6K	$95K	$0
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Board members representing outside shareholders (2)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 13, 2025	Sold	Held Oct 13, 2026	Still held
Tomer Kariv ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Tomer Kariv are complete. Director	n/a	−4.79M	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Tomer Kariv Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Tomer Kariv are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)
Carl Gordon ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Carl Gordon are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Carl Gordon Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Carl Gordon are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Is this normal? Selling year by year5 earlier years to compare with

Less than usual: about a quarter of the 5-year average. 9 insiders sold; the average is 2 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	39K	9	$523K
Oct 13, 2025 1 year earlier	0	0	$0
Oct 13, 2024 2 years earlier	80K	1	$3.6M
Oct 14, 2023 3 years earlier	40K	1	$1.9M
Oct 14, 2022 4 years earlier	288K	3	$13.7M
Oct 14, 2021 5 years earlier	424K	3	$21.8M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty14 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Keros Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology206 filings on record, 40 filed in the 12-month period, and how we read them

All 206 Forms 3, 4 and 5 on record for Keros Therapeutics, Inc. (SEC CIK 1664710), filed from Apr 7, 2020 to Aug 20, 2026; 40 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (8)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Christopher Rovaldi	Feb 19, 2025	60,000 shares, last reported balance as of Feb 18, 2025
Yung Chyung	Feb 19, 2025	44,000 shares, last reported balance as of Feb 18, 2025
Simon Cooper	Feb 15, 2024	No balance on record
Jennifer Lachey	Jul 19, 2022	95,100 shares, last reported balance as of Jul 15, 2022
Claudia Ordonez	Jun 15, 2021	No balance on record
Arkin Bio Ventures Limited Partnership	Apr 13, 2020	2,013,102 shares, last reported balance as of Apr 13, 2020
Alon Lazarus	Apr 13, 2020	23,038 shares, last reported balance as of Apr 13, 2020
Alon Lazarus	Apr 13, 2020	2,013,102 shares, last reported balance as of Apr 13, 2020

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Keros Therapeutics, Inc. insiders sold $523K in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Keros Therapeutics, Inc. CEO selling stock?

Why are Keros Therapeutics, Inc. insiders selling?

Are any Keros Therapeutics, Inc. insiders buying?

The evidence

Taxes

Purchases · 1 buyer (6 trades)

Sales by month